Publications by authors named "C Helten"
Article Synopsis
- Long-term factor Xa (FXa) inhibition shows promise in reducing inflammation and improving outcomes after heart attacks and strokes by impacting platelet function.
- In experiments with mice, chronic FXa inhibition led to smaller brain and heart injury sizes and better cardiac function compared to acute inhibition.
- Analysis of patients revealed that those receiving FXa inhibitors had reduced infarct sizes and showed changes in platelet proteins that suggest decreased release of substances that promote inflammation and clotting.
Background: Aortic valve disease (AVD) is associated with high mortality and morbidity. To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in osteogenic signaling, we examined the role of S1P signaling in aortic stenosis disease.
View Article and Find Full Text PDFBackground: Impella™ is increasingly used in cardiogenic shock. However, thromboembolic and bleeding events are frequent during percutaneous mechanical circulatory support (pMCS).
Objective: Therefore, we aimed to explore the optimal anticoagulation regime for pMCS to prevent thromboembolism and bleedings.
Rivaroxaban attenuates neutrophil maturation in the bone marrow niche.
Basic Res Cardiol
August 2023
Pharmacological inhibition of factor Xa by rivaroxaban has been shown to mediate cardioprotection and is frequently used in patients with, e.g., atrial fibrillation.
View Article and Find Full Text PDFAntiplatelet medication is standard of care in acute myocardial infarction (AMI). However, it may have obscured beneficial properties of the activated platelet secretome. We identify platelets as major source of a sphingosine-1-phosphate (S1P) burst during AMI, and find its magnitude to favorably associate with cardiovascular mortality and infarct size in STEMI patients over 12 months.
View Article and Find Full Text PDF